Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

Thomas A. Ciulla, Philip J Rosenfeld

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The discovery of VEGF-A's role in the pathogenesis of neovascular ocular disease provided a strong rationale for the development of anti-VEGF-based therapies. There is now ample evidence that anti-VEGF therapies are viable treatment options for these diseases. Nevertheless, large, randomized controlled trials are still awaited to confirm early safety and efficacy findings from small, open-label prospective studies.

Original languageEnglish
Pages (from-to)166-174
Number of pages9
JournalCurrent Opinion in Ophthalmology
Volume20
Issue number3
DOIs
StatePublished - May 1 2009

Fingerprint

Eye Diseases
Macular Degeneration
Vascular Endothelial Growth Factor A
Therapeutics
Randomized Controlled Trials
Prospective Studies
Safety

Keywords

  • Anti-vascular endothelial growth factor therapy
  • Bevacizumab
  • Neovascularization
  • Pegaptanib sodium
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. / Ciulla, Thomas A.; Rosenfeld, Philip J.

In: Current Opinion in Ophthalmology, Vol. 20, No. 3, 01.05.2009, p. 166-174.

Research output: Contribution to journalArticle

@article{b8e913af454f41029ea9ffef0c19bc08,
title = "Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration",
abstract = "Lippincott Williams & Wilkins.",
keywords = "Anti-vascular endothelial growth factor therapy, Bevacizumab, Neovascularization, Pegaptanib sodium, Ranibizumab",
author = "Ciulla, {Thomas A.} and Rosenfeld, {Philip J}",
year = "2009",
month = "5",
day = "1",
doi = "10.1097/ICU.0b013e328329d173",
language = "English",
volume = "20",
pages = "166--174",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

AU - Ciulla, Thomas A.

AU - Rosenfeld, Philip J

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - Anti-vascular endothelial growth factor therapy

KW - Bevacizumab

KW - Neovascularization

KW - Pegaptanib sodium

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=65549136672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549136672&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e328329d173

DO - 10.1097/ICU.0b013e328329d173

M3 - Article

VL - 20

SP - 166

EP - 174

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 3

ER -